Abstract
With the release of the survival results from the NELSON lung cancer screening trial there is now additional evidence that low-dose computed tomography (LDCT) screening leads to a reduction of lung cancer mortality in high-risk individuals. These results clearly show that LDCT screening has to be implemented in daily routine. However some questions like the most efficient screening intervals, duration of screening or the most appropriate participant selection are still not finally answered. This article provides a view on lung cancer screening from an oncologist’s perspective.
Highlights
Lung cancer remains the leading cause of cancer related death worldwide, mainly due to the presence of advanced disease in the majority of patients at the time of diagnosis [1]
Robust data from prospective, randomised trials evaluating the clinically most important endpoint of overall survival were lacking until in 2011 the National Lung Cancer Screening Trial (NLST) reported that annual low-dose computed tomography (CT) (LDCT) screening over a period of three years leads to a 20% reduction of lung-cancer-specific mortality compared to individuals undergoing annual screening by chest x-ray [7]
With the release of the survival results from the NELSON lung cancer screening trial there is additional evidence that LDCT screening leads to a reduction of lung cancer mortality in high-risk individuals
Summary
Summary With the release of the survival results from the NELSON lung cancer screening trial there is additional evidence that low-dose computed tomography (LDCT) screening leads to a reduction of lung cancer mortality in high-risk individuals. These results clearly show that LDCT screening has to be implemented in daily routine. Keywords Lung cancer · Low-dose computed tomography · Screening · Survival · NLST. The NELSON lung cancer screening trial is the so far second largest randomised trial showing that low-dose computed tomography (CT) screening reduces lung-cancer specific mortality in highrisk individuals. Keeping the dramatic stage shift observed in NELSON and NLST in mind, studies evaluating adjuvant and neoadjuvant therapeutic concepts have to be prioritized
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
